Amendments to the CLAIMS:

1. (previously presented) A peptide comprising a portion of an endostatin protein, wherein said peptide is of length from 7-20 amino acids long and contains a pair of proline residues at least one of which is a terminal residue or a residue penultimate to a terminus of the peptide, and wherein said peptide exhibits an IC_{50} of 20 μM or less in a bovine aorta endothelial cell proliferation assay or exhibits inhibition of angiogenesis in a chick chorioallantoic membrane assay of at least 30% at a dose of 50 μg/coverslip.

2. (original) The peptide of claim 1 that exhibits an IC_{50} of 20 nM to 20 mM in a bovine aorta endothelial cell assay or exhibits inhibition of angiogenesis in a chick chorioallantoic membrane assay of at least 50% at a dose of 10 to 25 μg/coverslip.

3. – 5. (cancelled).

6. (original) The peptide of claim 1 that lacks any cysteine or if it contains any cysteine, the cysteine is blocked to prevent disulfide formation.

7. (previously presented) The peptide of claim 1 that has a length of 9 to 20 amino acids.

8. (original) The peptide of claim 7 that lacks any cysteine or if it contains any cysteine, the cysteine is blocked to prevent disulfide formation.

9. (cancelled).

10. (previously presented) The peptide of claim 1, comprising a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 30-32.

11. & 12. (cancelled).

13. (original) A pharmaceutical composition comprising a peptide according to claim 1 and a pharmaceutically acceptable carrier.

14. (original) The composition according to claim 13, wherein said composition provides a unit dose of from 20 μg/kg/day to 2 mg/kg/day.

15. (original) A pharmaceutical composition comprising a peptide according to claim 10 and a pharmaceutically acceptable carrier.

16. (original) The composition according to claim 15, wherein said composition provides a unit dose of from 20 μg/kg/day to 2 mg/kg/day.

17. & 18. (cancelled).

19. (previously presented) A method for inhibiting angiogenesis in a tumor comprising administering to a subject at risk for or presenting a tumor an effective amount of the composition of claim 13 to a subject.

20. (original) A method for inhibiting angiogenesis in a tumor comprising administering to a subject at risk for or presenting a tumor an effective amount of the composition of claim 15 to a subject.

21. (cancelled).

22. & 23. (cancelled).

24. (cancelled).

25. (previously presented) The peptide of claim 10, comprising the peptide having the amino acid sequence of SEQ ID NO:30.

26. (previously presented) A pharmaceutical composition comprising the peptide according to claim 25 and a pharmaceutically acceptable carrier.

27. (previously presented) A method for inhibiting angiogenesis in a tumor comprising administering to a subject at risk for or presenting a tumor an effective amount of the composition of claim 26 to a subject.

28. (cancelled).

29. (previously presented) The peptide of claim 1, having two proline residues each being located penultimate to a terminus of the peptide.

30. (withdrawn) The peptide having the amino acid sequence of SEQ ID NO:29.

31. (withdrawn) The peptide of claim 10, comprising the peptide having the amino acid sequence of SEQ ID NO:31.

32. (withdrawn) The peptide of claim 10, comprising the peptide having the amino acid sequence of SEQ ID NO:32.